Literature DB >> 1906160

Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion.

A G Arguedas1, M Zaleska, H R Stutman, J L Blumer, C S Hains.   

Abstract

A total of 137 children with acute otitis media with effusion were randomly allocated to treatment with cefprozil (30 mg/kg/day divided into two equal doses), an investigational cephalosporin or amoxicillin clavulanate potassium (40 mg/kg/day divided into three equal doses) for 10 days. The most common pathogens obtained from middle ear cavities by tympanocentesis were Streptococcus pneumoniae (33%), Haemophilus influenzae (19.6%) and Moraxella catarrhalis (8.3%). Patients were scheduled for follow-up visits at midtreatment, at end of therapy and at 30 days. Of the 137 children 122 were evaluable. Five of 60 patients (8.3%) treated with cefprozil and 14 of 62 patients (22.5%) treated with amoxicillin clavulanate potassium were considered therapeutic failures because of persistence of symptoms and/or isolation of the original pathogen or superinfection (P = 0.05). Rates of relapse, reinfection and persistent middle ear effusion as documented by tympanogram were comparable in both groups. When persistent middle ear effusion was analyzed by pneumatic otoscopy, 64 of 103 affected ears (62.1%) treated with cefprozil and 80 of 105 affected ears (76.1%) treated with amoxicillin clavulanate potassium were abnormal (P = 0.04). Loose stools were more common in children treated with amoxicillin clavulanate potassium than in children treated with cefprozil (P = 0.0004). Based on the efficacy results from this study, the lower gastrointestinal side effects and the convenience of twice-a-day dosing, we believe that cefprozil in a dosage of 30 mg/kg/day divided every 12 hours represents a potential alternative for the treatment of acute otitis media with effusion in children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906160     DOI: 10.1097/00006454-199105000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 2.  Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials.

Authors:  Jemima Kuehn; Zareen Ismael; Paul F Long; Charlotte I S Barker; Mike Sharland
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

Review 3.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 4.  Cefprozil: a review.

Authors:  Sumit Bhargava; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

5.  Efficacy and tolerability assessment of cefprozil in children with acute otitis media.

Authors:  Nomeeta Gupta; Vivek Bagga; Bharat J Parmar; Kishaloy Kar; Abhijit Mukherjee; Sandip Mehta; Ashok K Moharana
Journal:  Indian J Pediatr       Date:  2004-04       Impact factor: 1.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.